Impact of endpoint selection on sample size calculations for disease-modifying clinical trials in Parkinson's disease patients with GBA1 mutations

被引:0
|
作者
Simon, David K. [1 ]
Mendonca, Nuno [2 ]
Holenz, Joerg [3 ]
Liu, Jennifer [1 ]
Castilla-Fernandez, Guillermo [2 ]
Fonseca, Miguel M. [3 ]
机构
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Bial R&D Investments SA, Coronado, Portugal
[3] Bial Portela & Ca SA, Coronado, Portugal
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
POSTER 28
引用
收藏
页码:S10 / S11
页数:2
相关论文
共 50 条
  • [21] GBA1 and The Immune System: A Potential Role in Parkinson's Disease?
    Al-Azzawi, Zaid A. M.
    Arfaie, Saman
    Gan-Or, Ziv
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 : S53 - S64
  • [22] Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson's disease
    Zhou, Yangjie
    Wang, Yige
    Wan, Juan
    Zhao, Yuwen
    Pan, Hongxu
    Zeng, Qian
    Zhou, Xun
    He, Runcheng
    Zhou, Xiaoxia
    Xiang, Yaqin
    Zhou, Zhou
    Chen, Bin
    Sun, Qiying
    Xu, Qian
    Tan, Jieqiong
    Shen, Lu
    Jiang, Hong
    Yan, Xinxiang
    Li, Jinchen
    Guo, Jifeng
    Tang, Beisha
    Wu, Heng
    Liu, Zhenhua
    NPJ PARKINSONS DISEASE, 2023, 9 (01)
  • [23] Levodopa-carbidopa intestinal gel for advanced Parkinson's ' s disease: Impact of LRRK2 and GBA1 mutations
    Thaler, Avner
    Anis, Saar
    Ponger, Penina
    Fay-Karmon, Tsviya
    Livneh, Vered
    Faust-Socher, Achinoam
    Greenbaum, Lior
    Reiner, Johnathan
    Hilel, Ariela
    Shabtai, Hertzel
    Alcalay, Roy N.
    Djaldetti, Ruth
    Hassin-Baer, Sharon
    Ezra, Adi
    Mirelman, Anat
    Giladi, Nir
    Gurevich, Tanya
    PARKINSONISM & RELATED DISORDERS, 2024, 127
  • [24] Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson’s disease
    Yangjie Zhou
    Yige Wang
    Juan Wan
    Yuwen Zhao
    Hongxu Pan
    Qian Zeng
    Xun Zhou
    Runcheng He
    Xiaoxia Zhou
    Yaqin Xiang
    Zhou Zhou
    Bin Chen
    Qiying Sun
    Qian Xu
    Jieqiong Tan
    Lu Shen
    Hong Jiang
    Xinxiang Yan
    Jinchen Li
    Jifeng Guo
    Beisha Tang
    Heng Wu
    Zhenhua Liu
    npj Parkinson's Disease, 9
  • [25] How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka, Abhishek
    Jankovic, Joseph
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (02) : 107 - 122
  • [26] Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
    Surface, Matthew
    Balwani, Manisha
    Waters, Cheryl
    Haimovich, Alexander
    Gan-Or, Ziv
    Marder, Karen S.
    Hsieh, Tammy
    Song, Linxia
    Padmanabhan, Shalini
    Hsieh, Frank
    Merchant, Kalpana M.
    Alcalay, Roy N.
    MOVEMENT DISORDERS, 2022, 37 (02) : 416 - 421
  • [27] Lack of full sequencing GBA1 studies for patients with Parkinson’s disease in Latin America
    Bruno Lopes Santos-Lobato
    Artur F. Schumacher-Schuh
    Ignacio F. Mata
    npj Parkinson's Disease, 8
  • [28] Lack of full sequencing GBA1 studies for patients with Parkinson's disease in Latin America
    Lopes Santos-Lobato, Bruno
    Schumacher-Schuh, Artur F.
    Mata, Ignacio F.
    NPJ PARKINSONS DISEASE, 2022, 8 (01)
  • [29] A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene
    Rodriguez-Traver, Eva
    Diaz-Guerra, Eva
    Rodriguez, Cesar
    Fernandez, Pablo
    Arenas, Fabian
    Arauzo-Bravo, Marcos
    Orera, Maria
    Kulisevsky, Jaime
    Moratalla, Rosario
    Vicario, Carlos
    STEM CELL RESEARCH, 2019, 38
  • [30] GBA1 in Parkinson's disease: variant detection and pathogenicity scoring matters
    Gabbert, Carolin
    Schaake, Susen
    Lueth, Theresa
    Much, Christoph
    Klein, Christine
    Aasly, Jan O.
    Farrer, Matthew J.
    Trinh, Joanne
    BMC GENOMICS, 2023, 24 (01)